Financial Performance
Amounts in ₹ crore; EPS in ₹ per share. PAT is total profit for the period, including non-controlling interests. Standalone statements.
Not yet reported for this period and basis.
01 · UNDERSTAND THE BUSINESS
The company in 60 seconds
Paras Health is the fifth largest healthcare provider by bed capacity in North India, Bihar, and Jharkhand, with 2,135 beds across eight hospitals as of March 31, 2024. Focused on providing specialized tertiary care in Tier 2 and 3 cities, Paras Health offers clinical specialties like cardiac sciences, oncology, and orthopedics. With 18 years of experience, the company has an asset-light business model, successfully expanding into underserved markets. It has plans to increase bed capacity to 2,935 by 2029 through new hospitals in Gurugram and Ludhiana. Paras Health also invests in digital healthcare solutions.
What supports the business
- One of the largest healthcare providers in underserved markets of North India, with a first-mover advantage in key regions.
- Asset-light business model focused on driving patient access and operational performance.
- Strong ability to attract and retain renowned clinicians, delivering high-quality clinical care.
- Diversified operations across multiple clinical specialties, payor mix, and geographic locations.
- Robust infrastructure with advanced information technology systems and modern medical equipment.
- Doctor-led professional management team with proven execution capabilities and deep industry expertise.
What could go wrong
- Incurred significant losses in recent years with no guarantee of future profitability.
- Reliant on attracting and retaining skilled healthcare professionals to maintain operations.
- Regulatory changes and pharmaceutical pricing uncertainties could harm financial performance.
- Dependence on in-patient revenue and occupancy rates affects profitability.
- Non-exclusive doctor arrangements risk disruption if key doctors leave.
- Non-compliance with regulations could severely impact business and finances.
Where will the IPO money go?
Use of proceeds is awaiting review.
Fresh issue proceeds go to the company. Offer-for-sale proceeds go to the selling shareholders.
Provider content · IPOALERTS · Not independently reviewed · Retrieved 3 Oct 2026, 12:08 pm IST · Data source ↗
A research starting point, not an apply/avoid recommendation.
02 · PREPARE YOUR APPLICATION
How much will be blocked?
Category rules pending · Unknown
Applications have not opened yet.
Application rules are awaiting review. Check the issue prospectus or your broker.
Before you finish applying 0/5
Your personal checklist for this visit. MeraIPO cannot verify or submit an application.
All checked? This still does not guarantee allotment. If a UPI mandate is missing, contact the broker or intermediary you used. ASBA through a bank may not use UPI.
Application help from NSE ↗03 · KEEP TRACK
Dates that matter
Tentative · check for changes- Applications openTo be announced
- Applications closeTo be announced
- Accept UPI mandate byTo be announced
- Allotment expectedTo be announced
- Unblocking startsTo be announced
- Expected listingTo be announced
All times are IST. Your broker may stop accepting bids earlier. Unblocking is an initiation date; bank processing times can differ.
Add dates to calendar ↓Import these dates into your calendar. Saved dates will not update automatically if the schedule changes.
Did you get shares?
The official registrar link is awaiting verification.
UPI mandate missing?
Check your UPI app and application status with the broker or bank you used. Contact that intermediary before the applicable deadline. Submitting a bid alone does not confirm that funds were blocked.
NSE application guidance ↗Market interest
Unofficial GMP
₹94
Implied price: —
An unofficial indication, not an exchange quote or a forecast. Listing prices may differ substantially.
16 Oct 2026, 3:00 pm IST · Stale
Financial history & source documents
BUSINESS VS PRICE
Insufficient Data / Price pending
Two comparable YoY results and EBITDA margins are required.
The quarterly journey
₹ Cr except EPS and ratios| Financial metric | IPO baseline |
|---|---|
| Revenue | — |
| Revenue YoY | — |
| Revenue QoQ | — |
| EBITDA | — |
| EBITDA YoY | — |
| EBITDA QoQ | — |
| EBITDA margin | — |
| Margin change QoQ (bps) | — |
| Margin change YoY (bps) | — |
| PAT | — |
| PAT YoY | — |
| PAT QoQ | — |
| EPS (₹) | — |
| Operating cash flow | — |
| Debt | — |
| ROE | — |
| ROCE | — |
Quarterly results are not available yet. The original IPO baseline is retained separately.
“—” means unavailable, not zero. Year-on-year growth requires a positive comparable period. Cash flow is shown only when reported for that period.
Annual financial history · latest four years
Separate from the original pre-IPO baseline. Amounts in ₹ crore; EPS in ₹.
No annual filings have been imported yet.
Stock journey
- Listing price
- —
- Since listing
- —
- All-time high
- —
- 52-week high / low
- — / —
Valuation snapshot
Data unavailable
- IPO P/E
- —
- Current P/E
- —
- Peer median P/E
- —
- Market cap (₹ Cr)
- —
- EV / EBITDA
- —
Sources & further research
Filing sources & update times
Source and verification record
Rhp url ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Status ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Exchange ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Board ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Sector ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Name ↗ · Unverified · 3 Oct 2026, 12:08 pm IST
Slug ↗ · Unverified · 3 Oct 2026, 12:08 pm IST